. 2022 Apr 26;11(2):459–476. doi: 10.1007/s40122-022-00381-1

Table 3.

Summary of in-human studies using less-invasive, incisionless MRgFUS for chronic pain

References	PN	Design	Target	Indication	FU	Outcome	SAE/AE
Non-invasive lesioning (non-reversible)
Gallay et al. [67]	8	PT	MRgFUS	TN	53 months	Mean pain relief 3 months: 51%	None
			Posterior part of the central lateral thalamic nucleus (peak 51–64 °C)			Mean pain relief 12 months: 71%
						Mean pain relief 53 months: 78%
Jeanmonod et al. [66]	12	PT	MRgFUS	NP	12 months	Mean pain relief 3 months: 49%	1 ICH
Jeanmonod et al. [66]	12	PT	Posterior part of the central lateral thalamic nucleus (peak 51–64 °C)	NP	12 months	Mean pain relief 12 months: 57%	1 ICH
Gallay et al. [65]	180 (treatments)	PT	MRgFUS	NP	3 months	Not reported	None
Gallay et al. [65]	180 (treatments)	PT	Posterior part of the central lateral thalamic nucleus (peak 51–64 °C)	NP	3 months	Not reported	None
Martin et al. [64]	9	PT	MRgFUS	NP	NA	Mean pain relief after 2 days: 68%	None
Martin et al. [64]	9	PT	VPL (peak temperature 51–60 °C)	NP	NA	Mean pain relief after 2 days: 68%	None

MRgFUS magnet resonance guided focused ultrasound, PT pilot study, RCT randomized controlled trial, CR case report, VPL nucleus ventrolateralis of the thalamus, CPSP chronic post-stroke pain, FU follow-up, SAE/AE serious adverse event, ICH intracranial haemorrhage, NP neuropathic pain, TN trigeminal neuralgia, NA not applicable